Table. Comparison of Pathologic Response From Investigational Treatments With Control Treatment^a.

Treatment	HR+/ERBB2-		HR-/ERBB2-		ERBB2+
	Not graduated	Graduated	Not graduated	Graduated	Not graduated	Graduated
Sample size	227	38	183	61	70	161
Odds ratio for response (investigational treatment vs control treatment)
pCR	1.00 (0.50 to 2.07)	2.35 (0.88 to 6.21)	2.72 (1.45 to 5.31)	5.63 (2.56 to 12.9)	1.43 (0.51 to 4.29)	4.59 (1.83 to 12.7)
pCR/RCB-I	1.34 (0.75 to 2.43)	2.41 (1.01 to 5.77)	1.87 (1.05 to 3.34)	5.84 (2.52 to 14.5)	1.12 (0.44 to 2.88)	2.31 (1.01 to 5.78)
Difference in median RCB value (investigational treatment vs control treatment)
RCB	−0.09	−0.19	−0.56	−1.46	−0.11	−1.36
P value	.55	.26	.002b	<.001b	.82	.003b

Abbreviations: HR, hormone receptor; pCR, pathologic complete response; RCB, residual cancer distribution.

^a Odds ratios for pathologic response (with 95% confidence interval) for the investigational arms treatments relative to control treatment. Investigational treatments were aggregated within phenotypic subset and categorized into those that did not graduate or did graduate from the I-SPY2 trial subtypes of breast cancer: HR+/ERBB2−, HR−/ERBB2−, and ERBB2+. Pathologic response is represented as rate of pCR alone, and as pCR or RCB-I. The sample size for controls was 92 for HR+/ERBB2−, 76 for HR−/ERBB2−, and 30 for ERBB2+.

^b The difference in median RCB value was compared using the Wilcoxon rank sum test.